|
|
|
| home > ebr > Summer 2013 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
New Finance Models
A Common Cause
Oliver Timmis at the AKU Society investigates how collaboration between medical research charities and patient organisations could fund vital studies.
|
|
|
|
|
Phage Prevention
Detection Validation
The presence of bacteriophages in fermentation and the facility environment needs to be constantly monitored by microbiologists. But when this is not possible, what other options are there? Marcin Los at Phage Consultants sheds light on this growing problem.
|
|
|
Rediscovery
More for Less
The advantages of drug repurposing are vast, however the development costs involved risk stifling this innovation, argues Bruce Bloom at Cures Within Reach.
|
|
|
Regulation and Finance
Tailored Medicine
With the help of a revised European Directive, bespoke treatments are entering the oncology industry and are being presented as safer and more effective, as Vincent O’Neill and Debasish Roychowdhury at Sanofi Oncology demonstrate.
|
|
|
Organism Development
All Systems Go
A new discipline has risen in recent years: systems biology. José Manuel Mas and Albert Pujol Torras at Anaxomics describe the two main strategies that are used in this scheme – the topological and the functional.
|
|
|
|
Genotoxicity Screening
Early Identification
Steve Beasley at Gentronix assesses the need for the early screening of genetic toxicity to minimise late-stage attrition costs and improve compound quality.
|
|
|
|
|
Drug Development
Tunable Half-Life Technology
Mark Perkins at Novozymes Biopharma analyses the challenges of biological drugs’ short half-lives, and how extension technology could resolve this problem.
|
|
|
|
Tailoring Treatments
Critical Overhaul
Rick Morrison at Comprehend Systems demonstrates how the combination of rising patient demands and pioneering new technology could be the solution to bespoke medicine.
|
|
|
Repurposing
Intelligent Approaches
In order to develop the drug discovery market and find indications for orphan conditions, alternative methods have to be implemented.Robert Scoffin and Alan Rothaul at Re-Pharm investigate the potential of drug repurposing or reprofiling to address this issue.
|
|
|
Anti-Infective Drugs
The PK/PD Complex
In revealing the specific distinctions of a compound, pharmacokinetic and pharmacodynamic properties are being used and are becoming an increasing area of interest, suggests medical author Deborah Erickson.
|
|
|
Cancer Therapy
The T Cell Promise
The evolution of the cancer therapy field is progressing through the help of T cells, which may eventually prove able to eradicate tumours. Namir J Hassan and Joanne Oates at Immunocore discuss the potential of this strategy.
|
|
|
|
Bioregional
Innovative India
Andrew Barrett at Cambridge Consultants illustrates how Indian pharmaceutical companies are planning to create super-generics, and how they could potentially become a major force in the connected health market.
|
|
|
|
Industry Interview
Insider Information
Jon Weisberg of SAFE-BioPharma reveals his career motivation and looks forward to the future of the biopharma sector.
|
|
|
|
Oncology Drugs
Purposeful Reprofiling
A burgeoning trend in cancer prevention has been the treatment of patients with drugs that have already been approved in therapeutic areas other than oncology, as Rachel Meighan-Mantha at Citeline explains.
|
|
|
Vaccines
Prevention is Better than Cure
Emanuela Signori at CNR-IFT and Vito Michele Fazio at UCBM discuss how recent research into the immune system biology has led to new strategies within the DNA vaccination area.
|
|
|
Gene Therapy
Great Promise
Introducing therapeutic genetic material into a disease cell to correct phentotypes is becoming a popular concept in curing monogenic conditions. Bobby Gaspar and Christine Rivat at UCL talk us through this model.
|
|
|
Protein Drugs
The Sugar is the Key
Taegen Clary at Agilent explains how analytical methods can aid the manufacturing process of protein biologics, which are especially important at a time of increasing patent expirations.
|
|
|
Detection Techniques
Identifying Impurities
Process-related contamination from host cells is a relentless problem that needs to be addressed. Andrew Kenyon at RSSL assesses the situation and suggests alternative methods to tackle this issue.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain
E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic
ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to
the pharmaceutical and chemical industry, announced the availability of
the Faubel-Med® Label, a smart label for investigational medicinal
products. The Med Label features E Ink’s low-voltage film technology,
bringing display modules and new system designs to pharmaceutical
packaging.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Amber™, featuring Pushclick Technology
SHL Group
The Amber™ Auto Injector is a single-dose, disposable auto injector with
a unique patient-centric industrial design. This device features
Pushclick™ technology, which enables it to be activated by simply
pushing against the injection site, a total of only 2 simple steps. The
unique ergonomic industrial design of the device provides various grip
options when removing the cap and when performing the injection. Safety
features and essential audible, visual and tactile feedback mechanisms
are also integrated into the device.
More info >> |
|
 |
Industry Events |
 |
14th Annual Biomarkers & Immuno-Oncology World Congress
11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts
The Biomarkers and Immuno-Oncology World
Congress brings together a unique and international mix of large and
medium pharmaceutical, biotech and diagnostics companies, leading universities
and clinical research institutions, government and national labs, CROs,
emerging companies and tool providers—making the Congress a perfect
meeting-place to share experience, foster collaborations across industry and
academia, and evaluate emerging technologies.
More info >> |
|
|
